# Unleashing endogenous regeneration by senolytics

**Authors:** Navneet K. Boddu, Santosh Kesari, Brandy A. Chavez, Anil Bajnath, Maxim D. Wheatley, Qianyi Zhang, Yiqiao Wang, Joseph Ellis, Emma Lin, Jorge Genovese, Maria Fatima N. Robles

PMC · DOI: 10.1186/s12967-025-07398-y · 2025-11-25

## TL;DR

This paper explores how removing senescent cells with senolytics can boost the body's natural ability to regenerate tissues, offering new hope for treating chronic diseases.

## Contribution

The paper introduces a novel perspective on aging-related regeneration decline, linking it to senescent cells and proposing senolytics as a way to enhance tissue repair.

## Key findings

- Senescent cells secrete factors that inhibit endogenous regeneration.
- Senolytic therapies may restore progenitor cell function by removing these cells.
- Combining senolytics with regenerative interventions could enhance tissue repair.

## Abstract

Regenerative medicine holds significant promise for the treatment of chronic diseases by harnessing the body’s innate capacity to repair and restore physiological function. However, regenerative activity declines markedly with age, a phenomenon traditionally attributed to depletion/exhaustion of progenitor cell pools. We propose an alternative, complementary mechanism: that age-associated accumulation of senescent cells contributes to impaired regeneration through the secretion of “anti-regenerative” factors. Senolytic therapies, which selectively eliminate senescent cells, may therefore exert therapeutic effects in part by de-repressing endogenous regenerative pathways. If senolytics restore progenitor cell function, their use in combination with interventions known to stimulate endogenous progenitor activity, yet not fully optimized for clinical translation, may provide a powerful strategy to enhance tissue repair. In this review, we examine current research on cellular senescence and the therapeutic potential of senolytics across diverse chronic disease contexts. We summarize the presence and role of endogenous regenerative cells in multiple organ systems and highlight mechanisms by which senescent cell-derived secretory factors inhibit regeneration. Finally, we propose potential applications in which senolytic therapy could be leveraged to augment both homeostatic regeneration and regeneration stimulated by therapeutic interventions.

## Full-text entities

- **Genes:** SOX2 (SRY-box transcription factor 2) [NCBI Gene 6657] {aka ANOP3, MCOPS3}, ATXN1 (ataxin 1) [NCBI Gene 6310] {aka ATX1, D6S504E, SCA1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, ABCA3 (ATP binding cassette subfamily A member 3) [NCBI Gene 21] {aka ABC-C, ABC3, EST111653, LBM180, SMDP3}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, Rbfox3 (RNA binding fox-1 homolog 3) [NCBI Gene 287847] {aka Hrnbp3, Neun, RGD1560070}, Il1b (interleukin 1 beta) [NCBI Gene 24494] {aka IL-1F2}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, CD74 (CD74 molecule) [NCBI Gene 972] {aka CLIP, DHLAG, HLADG, II, Ia-GAMMA, p33}, SFTPC (surfactant protein C) [NCBI Gene 6440] {aka BRICD6, PSP-C, SFTP2, SMDP2, SP-C}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}, FGF7 (fibroblast growth factor 7) [NCBI Gene 2252] {aka HBGF-7, KGF}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, ISL1 (ISL LIM homeobox 1) [NCBI Gene 3670] {aka ISLET1, Isl-1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364] {aka CKb4, Exodus, LARC, MIP-3-alpha, MIP-3a, MIP3A}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, FGFR1 (fibroblast growth factor receptor 1) [NCBI Gene 2260] {aka BFGFR, CD331, CEK, ECCL, FGFBR, FGFR-1}, FLT1 (fms related receptor tyrosine kinase 1) [NCBI Gene 2321] {aka FLT, FLT-1, VEGFR-1, VEGFR1}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, CGA (glycoprotein hormones, alpha polypeptide) [NCBI Gene 1081] {aka CG-ALPHA, FSHA, GPA1, GPHA1, GPHa, HCG}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, RARRES2 (retinoic acid receptor responder 2) [NCBI Gene 5919] {aka HP10433, TIG2}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}
- **Diseases:** neurocognitive defects (MESH:D002493), Amyotrophic Lateral Sclerosis (MESH:D000690), chronic inflammation (MESH:D007249), Parkinson disease (MESH:D010300), ischemic brain (MESH:D020520), cardiac (MESH:D006331), fracture (MESH:D050723), oncogenesis (MESH:D063646), endothelial dysfunction (MESH:D014652), status epilepticus (MESH:D013226), IR (MESH:D015427), heart attack (MESH:D009203), CLI (MESH:D000089802), pain (MESH:D010146), necrotic (MESH:D009336), ARDS (MESH:D012128), ischemic damage (MESH:D017202), cardiotoxicity (MESH:D066126), hypoxia (MESH:D000860), hypothyroidism (MESH:D007037), brain swelling (MESH:D001929), peripheral artery disease (MESH:D058729), diseases (MESH:D004194), adrenal gland dysfunction (MESH:D000307), Cardiovascular conditions (MESH:D002318), ischemia (MESH:D007511), heart failure (MESH:D006333), injury (MESH:D014947), radiation damage (MESH:D011832), metastasis (MESH:D009362), SCI (MESH:D013119), bone loss (MESH:D001847), Alzheimer's disease (MESH:D000544), atherogenesis (MESH:D050197), Diabetes mellitus (MESH:D003920), infertility (MESH:D007246), viral infections (MESH:D014777), Osteopenia (MESH:D001851), osteoporosis (MESH:D010024), age- (MESH:D019588), ulcers (MESH:D014456), Cancer (MESH:D009369), fibrosis (MESH:D005355), type 2 diabetes (MESH:D003924), ischemic stroke (MESH:D002544), brain damage (MESH:D001925), lung injuries (MESH:D055370), brain tumors (MESH:D001932), degenerative diseases (MESH:D019636), retinopathy (MESH:D058437), kidney failure (MESH:D051437), infarct (MESH:D007238), SASP (MESH:D008579), biliary injury (MESH:D001658), tissue injury (MESH:D017695), idiopathic pulmonary fibrosis (MESH:D054990), brain trauma (MESH:D000070642), stroke (MESH:D020521), ischemic (MESH:D002545)
- **Chemicals:** Dasatinib (MESH:D000069439), LPS (MESH:D008070), Fisetin (MESH:C017875), ROS (MESH:D017382), Quercetin (MESH:D011794), indomethacin (MESH:D007213), tamoxifen (MESH:D013629), ceramides (MESH:D002518), bromodeoxyuridine (MESH:D001973), metformin (MESH:D008687), Dasatanib (-), prostanoids (MESH:D011453), minocycline (MESH:D008911), Navitoclax (MESH:C528561)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** BV-2 — Mus musculus (Mouse), Transformed cell line (CVCL_0182)

---
Source: https://tomesphere.com/paper/PMC12649086